DBVT and DBV Related Headlines
Go Back- Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of March 31, 2026
- DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document
- DBV Technologies Reports Full Year 2025 Financial Results and Business Update
- DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing
- Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025
- DBV Technologies completes last patient visit in peanut patch trial
- DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years
- DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq
- DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq
- Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2025
- DBV Technologies announces filing of 2025 Half-Year Report ― Conditions for accessing or consulting the Report
- DBV Technologies Reports Second Quarter and Half-Year 2025 Financial Results
DBVT and DBV Related Press Releases
Go Back- Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of March 31, 2026
- DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document
- DBV Technologies Reports Full Year 2025 Financial Results and Business Update
- DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing
- Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025
- DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years
- DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq
- DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq
- Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2025
- DBV Technologies announces filing of 2025 Half-Year Report ― Conditions for accessing or consulting the Report
- DBV Technologies Reports Second Quarter and Half-Year 2025 Financial Results
DBVT and DBV Related SEC Filings
Go Back- Form 3 DBV Technologies S.A. For: Oct 30 Filed by: Lee Philina
- Form 8-K DBV Technologies S.A. For: Feb 28
- Form SCHEDULE 13G/A DBV Technologies S.A. Filed by: Venrock Healthcare Capital Partners II, L.P.
- Form SCHEDULE 13G/A DBV Technologies S.A. Filed by: CITADEL ADVISORS LLC
- Form SCHEDULE 13G DBV Technologies S.A. Filed by: MPM BioImpact LLC
- Form SCHEDULE 13G DBV Technologies S.A. Filed by: MPM BioImpact LLC
- Form SCHEDULE 13G/A DBV Technologies S.A. Filed by: Vivo Opportunity Fund Holdings, L.P.
- Form SCHEDULE 13G/A DBV Technologies S.A. Filed by: Invus Global Management, LLC
- Form SCHEDULE 13G DBV Technologies S.A. Filed by: Artisan Partners Limited Partnership
- Form 4 DBV Technologies S.A. For: Jan 29 Filed by: Mohideen Pharis
- Form 8-K DBV Technologies S.A. For: Jan 16
- Form SCHEDULE 13D/A DBV Technologies S.A. Filed by: BAKER BROS. ADVISORS LP
- Form 4 DBV Technologies S.A. For: Jan 12 Filed by: 667, L.P.
- Form SCHEDULE 13G/A DBV Technologies S.A. Filed by: JANUS HENDERSON GROUP PLC
- Form SCHEDULE 13D/A DBV Technologies S.A. Filed by: Bpifrance Participations SA
- Form SCHEDULE 13D/A DBV Technologies S.A. Filed by: Bpifrance Participations SA
- Form SCHEDULE 13D/A DBV Technologies S.A. Filed by: Bpifrance Participations SA
- Form 4 DBV Technologies S.A. For: Dec 17 Filed by: Bpifrance SA
- Form 8-K DBV Technologies S.A. For: Dec 16
- Form SCHEDULE 13G/A DBV Technologies S.A. Filed by: JANUS HENDERSON GROUP PLC
- Form SCHEDULE 13G DBV Technologies S.A. Filed by: JANUS HENDERSON GROUP PLC
- Form 4 DBV Technologies S.A. For: Nov 20 Filed by: Mohideen Pharis
- Form 4 DBV Technologies S.A. For: Nov 21 Filed by: Tasse Daniel
- Form 4 DBV Technologies S.A. For: Nov 21 Filed by: Trapp Kevin Michael
- Form 4 DBV Technologies S.A. For: Nov 21 Filed by: Boucinha Virginie
- Form SCHEDULE 13G/A DBV Technologies S.A. Filed by: Venrock Healthcare Capital Partners II, L.P.
- Form 3 DBV Technologies S.A. For: Nov 03 Filed by: Trapp Kevin Michael
- Form SCHEDULE 13D/A DBV Technologies S.A. Filed by: Bpifrance Participations SA
- Form 8-K DBV Technologies S.A. For: Oct 30
- Form 8-K DBV Technologies S.A. For: Oct 28
- Form 10-Q DBV Technologies S.A. For: Sep 30
- Form SCHEDULE 13G DBV Technologies S.A. Filed by: Invus Global Management, LLC
- Form 8-K DBV Technologies S.A. For: Sep 18
- Form 8-K DBV Technologies S.A. For: Sep 05
- Form 424B5 DBV Technologies S.A.
- Form SCHEDULE 13G/A DBV Technologies S.A. Filed by: Venrock Healthcare Capital Partners II, L.P.
- Form SCHEDULE 13G DBV Technologies S.A. Filed by: Adage Capital Management, L.P.
- Form 4 DBV Technologies S.A. For: Jul 29 Filed by: Mohideen Pharis
- Form 8-K DBV Technologies S.A. For: Jul 29
- Form 10-Q DBV Technologies S.A. For: Jun 30
- Form 8-K DBV Technologies S.A. For: Jun 25
- Form S-8 DBV Technologies S.A.
- Form 8-K DBV Technologies S.A. For: Jun 11
